Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies

This article was originally published in RPM Report

Executive Summary

The debate over comparative effectiveness research has focused heavily on standards of evidence to judge the relative value of different therapies and standards for when and how conclusions should drive coverage policy. Less attention has been paid to a more fundamental question: when should the value determination be made. CMS’ top coverage official has an idea that would radically change that process.

Related Content

CMS Takes A Look At Alzheimer’s With Lilly's Amyvid In Mind
Carving-In Innovation: Payment Reform and Biopharma
Accelerated Withdrawal in Action: The Avastin Hearing Process
The Avastin Docket: Few Comments, But Lots of Questions About Implications
Dendreon vs. CMS: "Full Coverage" or the CED Solution?
Dendreon vs. CMS:Controversy Is Bigger Than One Product
The Avandia Re-Review: Three Scenarios
The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts